To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

Novartis

Status and phase: Completed; Phase 2

Conditions: Alzheimer Disease

Treatments: Biological: CAD106

Study type: Interventional

Funder types: Industry

Identifiers

NCT01023685

CCAD106A2202E1

Details and patient eligibility

About

This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.

Enrollment: 24 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have completed the core study with no significant safety concerns

Exclusion criteria

• Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression).
• Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease.
• Diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

CAD106

Experimental group

Treatment:

Biological: CAD106